Horizon Entered into an Option Agreement with Q32 Bio to Develop ADX-914 for the Treatment of Autoimmune Diseases


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Source link

Leave A Reply

Your email address will not be published.